Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 3Thyroid Cancer, Papillary 2Sarcoma 2Salivary Gland Neoplasms 2Neoplasm Metastasis 2Glioma 2Central Nervous System Neoplasms 2Wilms Tumor 1Solid Tumors 1Sarcoma, Ewing 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Nephroma, Mesoblastic 1Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 57Nivolumab 50Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × entrectinib × 90 days × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡